Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IKNA
- Price
- -
- Stock movement up
- +0.72 (4.38%)
- Company name
- Ikena Oncology Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 718.82M
- Ent value
- 688.39M
- Price/Sales
- 1090.78
- Price/Book
- 5.36
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -14.88%
- 3 year return (CAGR)
- -36.17%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-09-12
DIVIDENDS
IKNA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1090.78 |
| Price to Book | 5.36 |
| EV to Sales | 1044.60 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 41.89M |
| EPS (TTM) | -14.82 |
| FCF per share (TTM) | -15.37 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 659.00K |
| Gross profit (TTM) | 43.00K |
| Operating income (TTM) | -65.10M |
| Net income (TTM) | -59.60M |
| EPS (TTM) | -14.82 |
| EPS (1y forward) | -9.00 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 6.53% |
| Operating margin (TTM) | -9878.45% |
| Profit margin (TTM) | -9043.85% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 45.19M |
| Net receivables | 0.00 |
| Total current assets | 141.53M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 148.99M |
| Accounts payable | 1.54M |
| Short/Current long term debt | 8.39M |
| Total current liabilities | 9.24M |
| Total liabilities | 14.76M |
| Shareholder's equity | 134.23M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -61.56M |
| Capital expenditures (TTM) | 262.00K |
| Free cash flow (TTM) | -61.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -44.40% |
| Return on Assets | -40.00% |
| Return on Invested Capital | -43.14% |
| Cash Return on Invested Capital | -44.75% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| IKNA | S&P500 | |
| Current price drop from All-time high | -95.53% | - |
| Highest price drop | -96.78% | -19.00% |
| Date of highest drop | 7 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -82.96% | -2.49% |
| Avg time to new high | 544 days | 6 days |
| Max time to new high | 1088 days | 89 days |
COMPANY DETAILS
Marketcap
718.82M
Marketcap category
Small-cap
Description
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd.
Employees
9
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner